论文部分内容阅读
目的评价应用预混胰岛素治疗血糖控制不佳的T2DM患者转换为甘精胰岛素联合口服药物治疗的有效性及安全性。方法选择62例应用预混胰岛素治疗但血糖控制不佳的T2DM患者,将其治疗方案转换为甘精胰岛素联合口服药治疗16周。以治疗前后FPG、2hPG及HbA1c的变化评价方案的有效性和低血糖发生率及BMI的变化评价治疗的安全性,采用调查问卷评分比较治疗前后满意度。结果治疗16周后,FPG、2hPG及HbA1c较治疗前下降(P<0.01),HbA1c下降幅度大于1%者占63.79%;治疗期间共有16例发生非重度日间低血糖27次;患者对治疗的满意度较治疗前增加(P<0.01)。结论应用预混胰岛素治疗但血糖控制不佳的T2DM患者转换为甘精胰岛素联合口服药物治疗具有安全性、有效性。
Objectives To evaluate the effectiveness and safety of insulin-modified insulin as an oral medication for the treatment of T2DM with poor glycemic control. Methods Sixty-two patients with T2DM who were treated with premixed insulin but had poor glycemic control were enrolled. The treatment regimen was switched to insulin glargine plus oral medication for 16 weeks. The changes of FPG, 2hPG and HbA1c before and after treatment were evaluated by evaluating the effectiveness of the program and the changes of hypoglycemia and BMI. The questionnaire scores were used to compare the satisfaction before and after treatment. Results After 16 weeks of treatment, the FPG, 2hPG and HbA1c levels decreased significantly (P <0.01), the HbA1c level decreased more than 1% (63.79%); during the treatment period, 16 patients had non-severe hypoglycemia 27 times; Satisfaction than before treatment increased (P <0.01). Conclusions It is safe and effective to convert insulin glargine plus oral medication into T2DM patients with premixed insulin therapy and poorly controlled blood glucose level.